MD-CERTIS-BIOLOGICALS
11.8.2021 15:19:08 CEST | Business Wire | Press release
To meet the rising demand for biological-based crop protection products, Certis Biologicals today announced new additions to its headquarters team. Tarang Srivastava begins immediately as Head of International Business, responsible for business strategy and financial objectives in international markets and working with distribution partners, external business partners and internal teams to expand biologicals globally. Srivastava’s focus will lay in providing solutions to growers in European markets. Srivastava formally worked on Bharat Certis Insecticide Limited for parent company Mitsui & Co. and brings extensive experience in establishing global positions to the new role.
Additionally, Certis Biologicals welcomes Moto Mitani to the International Business Team. Mitani will lead the Certis teams for Asia and Africa as well as supporting Certis Biologicals’ Specialty Chemical Sales division. Mitani joins from Mitsui AgriScience where he served as Business Manager responsible for international sales.
Amanda Eade joins the Global Marketing Team as Global Portfolio Manager for Bioinsecticides and Bioherbicides, assessing market capacity for Certis’ proven portfolio of bio-based insecticide and herbicide solutions, including Bt portfolio products, Firefighter© , Requiem Prime© and Homeplate© . Eade brings extensive experience from posts with Open Book Extracts as Operations Manager, BASF as portfolio manager and Dow Agrisciences as sales representative.
“Currently, Certis Biologicals distributes bio-based solutions in more than 50 countries worldwide and we see a growing need in areas where synthetic chemistries are growing scarce and regulations are high,” says Amy O’Shea, President and CEO. “We want to ensure that every grower, no matter where they are located, has access to our portfolio and we believe these additions to our staff will be key to achieving that goal.”
The additions of Srivastava, Mitani and Eade come in the wake of Certis Biologicals’ announcement that Rob Gibson joined as Global Product Manager and Ryutaro Matsuhashi, VP of International Business, had expanded his role within the biologicals leader to focus on growth in Latin America. In that capacity, Matsuhashi has seen success in expanding the company’s portfolio in Brazil.
“We are proud to be headquartered in the U.S., but Certis Biologicals is a true global distributor of biologicals,” says O’Shea. “We are investing in the talent and expertise needed to ensure that we can be the full-line provider of biologicals to all growers and distributors.”
Currently, Certis Biologicals innovates across six technology platforms, including bacteria-based technologies, fungi-based products, virus technologies, bacteriophage technologies, biochemicals and need-seed extracts. The company distributes nearly 40 integrated biological crop protection solutions to growers in more than 50 countries. Certis’ robust research and development pipeline is planning numerous new products and formulations coming to market over the next 3-5 years.
Growers and distributors who are interested in Certis Biologicals can visit www.CertisBio.com to learn more about the company’s portfolio of bio-solutions for organic and conventional farming.
About Certis Biologicals
Certis Biologicals is the leading manufacturer, innovator, developer and marketer of proven biological solutions for use in commercial agriculture and the garden and greenhouse markets.
With biological products sold through a global distribution network and in collaboration with various technology, regulatory and sourcing companies in more than 50 countries, Certis Biologicals meets the challenges faced by today’s growers around the globe to feed a growing population while sustaining the natural resources and environments necessary for a healthy planet.
To learn more about Certis Biologicals, their portfolio of proven solutions, or their commitment to sustainability, visit www.CertisBio.com or follow the company through social media on Facebook , Twitter , LinkedIn and Instagram .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210811005074/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HTEC Research: Only One in Three Healthcare Organizations is Ready to Scale AI28.4.2026 15:22:00 CEST | Press release
Healthcare and life sciences leaders are advancing AI with caution—fragmentation, capability gaps, and execution challenges are slowing enterprise-wide impact AI is already embedded across healthcare and life sciences. Most organizations are deploying it, and confidence in its potential is high. Yet for many, the real challenge is only just beginning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428872907/en/ HTEC, a global AI‑first provider of software and hardware design and engineering services, today released new research based on a global survey of 253 C-level HLS executives across the United States, United Kingdom, Germany, Spain, Saudi Arabia, and the UAE. AI is already embedded across healthcare and life sciences. Most organizations are deploying AI, and confidence in its potential is high. Yet for many, the real challenge is only just beginning. HTEC, a global AI‑first provider of software and hardware design a
JPMorganChase Named First-Ever Global Banking Partner of the Olympic Games28.4.2026 15:00:00 CEST | Press release
International Olympic Committee and JPMorganChase Announce Landmark Global Olympic Partnership The International Olympic Committee (IOC) and JPMorganChase today announced a landmark Worldwide Olympic Partnership, making JPMorganChase the first Global Banking Partner in Olympic history. The partnership includes the Los Angeles 2028 Olympic and Paralympic Games (LA28 Games) and the French Alps 2030 Olympic and Paralympic Winter Games. The firm has also reached an agreement with LA28 to become the Official Bank of Team USA and LA28, and a Founding Partner of the LA28 Games. The partnership reflects a shared commitment to ambition and excellence, and places athletes and communities at its core. Kirsty Coventry, President of the IOC, commented: “JPMorganChase is the first Global Partner from the banking sector in Olympic history, and we are proud to welcome them to the Worldwide Olympic Partner programme. This partnership reflects our shared values of ambition, excellence and will support t
BlueSnap, Powered by Payroc, Launches Local Acquiring in New Zealand to Boost Approval Rates and Reduce Cross-Border Costs28.4.2026 15:00:00 CEST | Press release
BlueSnap, powered by Payroc, today announced the availability of local acquiring in New Zealand, expanding its global payment orchestration capabilities and enabling businesses to process transactions domestically. Local acquiring allows businesses with a legal entity in New Zealand to process payments through domestic acquiring banks rather than routing transactions cross-border. This helps increase authorization rates, reduce payment failures, and lower transaction costs, critical factors for businesses selling into the region. Why Local Acquiring in New Zealand Matters For B2B and B2C businesses operating globally, cross-border payments often lead to higher fees and lower approval rates. Building local acquiring infrastructure independently requires managing multiple bank relationships, compliance, and integrations, making it costly and complex. BlueSnap simplifies this by providing local acquiring through a single platform, allowing businesses with a legal entity in New Zealand to
Vensica Medical Receives FDA IND Clearance to Initiate Phase 2 Study of ViXe, Its Needle-Free Xeomin® Delivery System for Overactive Bladder28.4.2026 14:42:00 CEST | Press release
Vensica Medical, a clinical-stage company developing needle-free therapeutic delivery solutions for urologic diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of ViXe. The study will evaluate the Vibe® ultrasound-based, needle-free drug delivery system in combination with Xeomin® (incobotulinumtoxinA) for the treatment of overactive bladder (OAB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414145279/en/ Avner Geva, Cofounder, CEO (left), and Avi Eftel, Cofounder, CTO (right) Overactive bladder affects an estimated 33 million adults in the United States and is characterized by urinary urgency, frequency, and incontinence. While intravesical botulinum toxin injection is an established second-line treatment, the invasive procedure limits patient access and acceptance. The ViXe program is desi
Printing the Future of Oncology: CTIBIOTECH Invests €3M and Secures €1.25M from France 2030 to Revolutionize Personalized Cancer Care28.4.2026 14:28:00 CEST | Press release
CTIBIOTECH™, a leading innovator in advanced human tissue engineering, proudly announces CTIONCOTEST™ platform is awarded Major Bpifrance Funding to Industrialize 3D Bioprinted Cancer Models CTIBIOTECH Announces the CTIONCOTEST ™ Project to Revolutionize Cancer Research with 3D Bioprinted Microtumors, Backed by France 2030 and Bpifrance This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428242352/en/ The CTIONCOTEST™ platform by CTIBIOTECH is an innovative 3D bioprinting technology that revolutionizes preclinical cancer research . It provides an automated, industrial-scale process to produce high-throughput, patient-specific human "microtumors" directly from primary tumor cells . Designed to tackle the 95% clinical failure rate of new cancer drugs, it faithfully replicates the complex tumor microenvironment, including critical hypoxic and necrotic zones . Targeting high-mortality breast, colon, and pancreatic cancers, the pla
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom